Intrexon, a US-based synthetic biology company, has closed its series E round at $100m, bringing the company’s total capital raised to more than $259m.
New investors took the majority of the round while existing investors, including billionaire Randal Kirk, Intrexon’s executive chairman, through his Third Security venture investment unit, and Sandbox Industries, a venture capital firm that manages health service provider Blue Cross money.
Investment bank Perella Weinberg Partners was Intrexon’s financial adviser and placement agent on the round.
